Literature summary for 2.3.1.43 extracted from

Koukos, G.; Chroni, A.; Duka, A.; Kardassis, D.; Zannis, V.I.
Naturally occurring and bioengineered apoA-I mutations that inhibit the conversion of discoidal to spherical HDL: the abnormal HDL phenotypes can be corrected by treatment with LCAT (2007), Biochem. J., 406, 167-174.

Search for more literature for 2.3.1.43

Application

Application	Comment	Organism
medicine	the correction of the aberrant HDL phenotypes by treatment with LCAT suggests a potential therapeutic intervention for HDL abnormalities that result from specific mutations in apoA-I	Homo sapiens

Protein Variants

Protein Variants	Comment	Organism
additional information	using adenovirus-mediated gene transfer of the mutants apoA-I(R151C), apoA-I(R160L) and apoA-I(R149A) in apoA-I-/- mice, a common feature of the three mutations are observed: low HDL levels and the presence of discoidal particles in plasma. These defects can be corrected by coinfection of apoA-I-/- mice with adenoviruses expressing the mutant proteins along with human LCAT, indicating that the endogenous LCAT is rate limiting in the conversion of discoidal into spherical HDL	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Synonyms

Synonyms	Comment	Organism
LCAT	-	Homo sapiens
lecithin-cholesterol acyltransferase	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)